Trade Summary

5 days ago, Valantine Hannah, serving as Dir at Bridgebio Pharma, Inc. (BBIO), sold 8,671 shares at $72.00 per share, for a total transaction value of $624,312.00. Following this transaction, Valantine Hannah now holds 7,863 shares of BBIO.

This sale represents a 52.00% decrease in Valantine Hannah's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 10, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 12, 2026, 2 days after the trade was made.

Bridgebio Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.